Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey
Identifieur interne : 001A67 ( Main/Exploration ); précédent : 001A66; suivant : 001A68Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey
Auteurs : Mehmet Ungan [Turquie] ; Hakan Kulaçog Lu [Turquie] ; Burçak Kayhan [Turquie]Source :
- Current Therapeutic Research [ 0011-393X ] ; 2001.
Abstract
Background: Helicobacter pylori is the main causative agent in peptic ulcer disease. Duodenal ulcer disease is a chronic, recurring condition, and the risk of recurrence and complications does not diminish over time unless H pylori is eradicated. Several treatment protocols exist to eradicate H pylori, but their efficacy and costs vary. Because of regional variations in bacterial resistance and in treatment costs, primary care physicians must use the most appropriate protocol for their own region and population. Objective: The primary aim of this study was to compare the cure rates obtained with 5 different H pylori eradication protocols in H pylori—positive duodenal ulcer patients in Turkey. A secondary objective was to determine the accuracy of the duodenal ulcer diagnoses made by primary care physicans relying on information from physical examination and medical history alone. Methods: In a primary care setting, 2 family physicians, 5 general physicians (medical school graduates), 1 general surgeon, and 1 internal medicine specialist identified 265 symptomatic duodenal ulcer patients using medical history and physical examination results. These patients were referred to an open-access endoscopy unit for upper gastrointestinal endoscopy. Patients who had an endoscopically confirmed duodenal ulcer and who tested positive for H pylori were randomly assigned to receive 1 of 5 H pylori eradication treatments: (1) omeprazole/amoxicillin/clarithromycin; (2) lansoprazole/amoxicillin/clarithromycin; (3) omeprazole/ornidazole/amoxicillin; (4) lansoprazole/amoxicillin/clarithromycin/ornidazole, or (5) ranitidine bismuth citrate/amoxicillin/metronidazole. Follow-up endoscopies and biopsies were performed 6 weeks and 6 months after the end of treatment. Results: Of the 265 patients suspected to have duodenal ulcers based on medical history and physical examination findings, 181 (68.3%) had endoscopically confirmed duodenal ulcers. At both 6 weeks and 6 months after treatment, eradication rate were not significantly different between treatment groups in the intent-to-treat or per-protocol analyses. There was no significant difference in tolerability between the 5 regimens. Conclusions: Our results confirm the high accuracy of the duodenal ulcer diagnoses and endoscopy referrals made by primary care physicians based on physical examination and medical history of the patient. Primary care physicians should play an important role in treatment decisions regarding H pylori eradication. The 5 treatments studied are similar with respect to H pylori eradication rates. If the cost of treatment is an important consideration, the less expensive omeprazole/ornidazole/amoxicillin triple regimen may be a good choice for eradicating H pylori. In cases of resistant H pylori infection, the lansoprazole/amoxicillin/clarithromycin/ornidazole quadruple therapy appears to be the best choice for a second-line treatment if reliable culture and resistance testing are not available. Depending on regional variables, each nation needs to develop its own guidelines for the eradication of H pylori.
Url:
DOI: 10.1016/S0011-393X(01)80057-6
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000421
- to stream Istex, to step Curation: 000421
- to stream Istex, to step Checkpoint: 001467
- to stream Main, to step Merge: 001A77
- to stream Main, to step Curation: 001A67
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey</title>
<author><name sortKey="Ungan, Mehmet" sort="Ungan, Mehmet" uniqKey="Ungan M" first="Mehmet" last="Ungan">Mehmet Ungan</name>
</author>
<author><name sortKey="Kulacog Lu, Hakan" sort="Kulacog Lu, Hakan" uniqKey="Kulacog Lu H" first="Hakan" last="Kulaçog Lu">Hakan Kulaçog Lu</name>
</author>
<author><name sortKey="Kayhan, Burcak" sort="Kayhan, Burcak" uniqKey="Kayhan B" first="Burçak" last="Kayhan">Burçak Kayhan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7C5E6B9B68933B5023CD85B3EB933E66B49715AD</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1016/S0011-393X(01)80057-6</idno>
<idno type="url">https://api.istex.fr/document/7C5E6B9B68933B5023CD85B3EB933E66B49715AD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000421</idno>
<idno type="wicri:Area/Istex/Curation">000421</idno>
<idno type="wicri:Area/Istex/Checkpoint">001467</idno>
<idno type="wicri:doubleKey">0011-393X:2001:Ungan M:cure:rates:obtained</idno>
<idno type="wicri:Area/Main/Merge">001A77</idno>
<idno type="wicri:Area/Main/Curation">001A67</idno>
<idno type="wicri:Area/Main/Exploration">001A67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey</title>
<author><name sortKey="Ungan, Mehmet" sort="Ungan, Mehmet" uniqKey="Ungan M" first="Mehmet" last="Ungan">Mehmet Ungan</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Middle East Tehnical University Medical Center, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Turquie</country>
</affiliation>
</author>
<author><name sortKey="Kulacog Lu, Hakan" sort="Kulacog Lu, Hakan" uniqKey="Kulacog Lu H" first="Hakan" last="Kulaçog Lu">Hakan Kulaçog Lu</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Middle East Tehnical University Medical Center, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kayhan, Burcak" sort="Kayhan, Burcak" uniqKey="Kayhan B" first="Burçak" last="Kayhan">Burçak Kayhan</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Middle East Tehnical University Medical Center, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Current Therapeutic Research</title>
<title level="j" type="abbrev">CUTHRE</title>
<idno type="ISSN">0011-393X</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="2001">2001</date>
<biblScope unit="volume">62</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="462">462</biblScope>
<biblScope unit="page" to="472">472</biblScope>
</imprint>
<idno type="ISSN">0011-393X</idno>
</series>
<idno type="istex">7C5E6B9B68933B5023CD85B3EB933E66B49715AD</idno>
<idno type="DOI">10.1016/S0011-393X(01)80057-6</idno>
<idno type="PII">S0011-393X(01)80057-6</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0011-393X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Helicobacter pylori is the main causative agent in peptic ulcer disease. Duodenal ulcer disease is a chronic, recurring condition, and the risk of recurrence and complications does not diminish over time unless H pylori is eradicated. Several treatment protocols exist to eradicate H pylori, but their efficacy and costs vary. Because of regional variations in bacterial resistance and in treatment costs, primary care physicians must use the most appropriate protocol for their own region and population. Objective: The primary aim of this study was to compare the cure rates obtained with 5 different H pylori eradication protocols in H pylori—positive duodenal ulcer patients in Turkey. A secondary objective was to determine the accuracy of the duodenal ulcer diagnoses made by primary care physicans relying on information from physical examination and medical history alone. Methods: In a primary care setting, 2 family physicians, 5 general physicians (medical school graduates), 1 general surgeon, and 1 internal medicine specialist identified 265 symptomatic duodenal ulcer patients using medical history and physical examination results. These patients were referred to an open-access endoscopy unit for upper gastrointestinal endoscopy. Patients who had an endoscopically confirmed duodenal ulcer and who tested positive for H pylori were randomly assigned to receive 1 of 5 H pylori eradication treatments: (1) omeprazole/amoxicillin/clarithromycin; (2) lansoprazole/amoxicillin/clarithromycin; (3) omeprazole/ornidazole/amoxicillin; (4) lansoprazole/amoxicillin/clarithromycin/ornidazole, or (5) ranitidine bismuth citrate/amoxicillin/metronidazole. Follow-up endoscopies and biopsies were performed 6 weeks and 6 months after the end of treatment. Results: Of the 265 patients suspected to have duodenal ulcers based on medical history and physical examination findings, 181 (68.3%) had endoscopically confirmed duodenal ulcers. At both 6 weeks and 6 months after treatment, eradication rate were not significantly different between treatment groups in the intent-to-treat or per-protocol analyses. There was no significant difference in tolerability between the 5 regimens. Conclusions: Our results confirm the high accuracy of the duodenal ulcer diagnoses and endoscopy referrals made by primary care physicians based on physical examination and medical history of the patient. Primary care physicians should play an important role in treatment decisions regarding H pylori eradication. The 5 treatments studied are similar with respect to H pylori eradication rates. If the cost of treatment is an important consideration, the less expensive omeprazole/ornidazole/amoxicillin triple regimen may be a good choice for eradicating H pylori. In cases of resistant H pylori infection, the lansoprazole/amoxicillin/clarithromycin/ornidazole quadruple therapy appears to be the best choice for a second-line treatment if reliable culture and resistance testing are not available. Depending on regional variables, each nation needs to develop its own guidelines for the eradication of H pylori.</div>
</front>
</TEI>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Ungan, Mehmet" sort="Ungan, Mehmet" uniqKey="Ungan M" first="Mehmet" last="Ungan">Mehmet Ungan</name>
</noRegion>
<name sortKey="Kayhan, Burcak" sort="Kayhan, Burcak" uniqKey="Kayhan B" first="Burçak" last="Kayhan">Burçak Kayhan</name>
<name sortKey="Kulacog Lu, Hakan" sort="Kulacog Lu, Hakan" uniqKey="Kulacog Lu H" first="Hakan" last="Kulaçog Lu">Hakan Kulaçog Lu</name>
<name sortKey="Ungan, Mehmet" sort="Ungan, Mehmet" uniqKey="Ungan M" first="Mehmet" last="Ungan">Mehmet Ungan</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Belgique |area= OpenAccessBelV2 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:7C5E6B9B68933B5023CD85B3EB933E66B49715AD |texte= Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey }}
This area was generated with Dilib version V0.6.25. |